Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)
BACKGROUND: The antimalarial artesunate (ART), a semisynthetic derivative of artemisinin from the Chinese herb artemisia annua has remarkable anticancer properties in vitro and in vivo. Its excellent safety profile known from short-term therapy in malaria was confirmed in an open phase I trial (ARTI...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2019
|
| In: |
Phytomedicine
Year: 2019, Volume: 54, Pages: 140-148 |
| ISSN: | 1618-095X |
| DOI: | 10.1016/j.phymed.2018.09.178 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.phymed.2018.09.178
|
| Author Notes: | Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, Brigitte Storch-Hagenlocher, Serkan Sertel, Michael Elsässer, Bjoern A. Remppis, Judith Munzinger, Lutz Edler, Thomas Efferth, Andreas Schneeweiss, Thomas Strowitzki |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662773706 | ||
| 003 | DE-627 | ||
| 005 | 20230426154239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190403s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phymed.2018.09.178 |2 doi | |
| 035 | |a (DE-627)1662773706 | ||
| 035 | |a (DE-599)KXP1662773706 | ||
| 035 | |a (OCoLC)1341205922 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hagens, Cornelia von |e VerfasserIn |0 (DE-588)1069452521 |0 (DE-627)821926632 |0 (DE-576)429165358 |4 aut | |
| 245 | 1 | 0 | |a Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2) |c Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, Brigitte Storch-Hagenlocher, Serkan Sertel, Michael Elsässer, Bjoern A. Remppis, Judith Munzinger, Lutz Edler, Thomas Efferth, Andreas Schneeweiss, Thomas Strowitzki |
| 264 | 1 | |c 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.04.2019 | ||
| 520 | |a BACKGROUND: The antimalarial artesunate (ART), a semisynthetic derivative of artemisinin from the Chinese herb artemisia annua has remarkable anticancer properties in vitro and in vivo. Its excellent safety profile known from short-term therapy in malaria was confirmed in an open phase I trial (ARTIC M33/2) for dose-finding as add-on therapy for four weeks. - PURPOSE: Patients with metastatic breast cancer, who had not experienced any clinically relevant adverse events (AE) during participation in ARTIC M33/2, were offered to continue ART as compassionate use (CU). Regular monitoring was continued in order to ensure adequate individual safety and tolerability and to collect information about long-term treatment with ART. Clinically relevant AEs or second progression of disease during ART were reasons for discontinuation of the add-on therapy. - STUDY DESIGN: Compassionate use was offered open-label to participants of ARTIC M33/2. - METHODS: Patients continued to take 100, 150 or 200mg oral ART daily as add-on therapy to their guideline-based oncological therapy. Clinical and laboratory monitoring included audiological and neurological examination, ECG, NTproBNP and reticulocyte determination. Cumulative treatment days and cumulative ART doses encompass both the phase I study as well as the continued add-on treatment period (CU). - RESULTS: Following the 4±1 weeks of the phase I trial, thirteen patients continued the add-on therapy as CU, resulting in a total of 3825 treatment days. In individual patients up to 1115 cumulative treatment days (37 months) and cumulative ART doses up to 167.3g were reached. A total of 25 AEs grade≥2 at least possibly related to ART long-term add-on therapy were documented, two, six and 17 in dose groups 100, 150 and 200mg/d ART respectively. Six of these AEs were classified as grade 3, two in patients taking 150 and four in patients on 200mg/d, none of them being probably or certainly related to ART. - CONCLUSIONS: In thirteen patients with metastatic breast cancer up to 200mg/d long-term oral ART (2.3-4.1mg/kg BW/d) in up to 1115 cumulative treatment days (37 months) did not result in any major safety concerns. | ||
| 700 | 1 | |a Walter-Sack, Ingeborg |e VerfasserIn |0 (DE-588)1065347987 |0 (DE-627)815887957 |0 (DE-576)425021408 |4 aut | |
| 700 | 1 | |a Goeckenjan, Maren |d 1970- |e VerfasserIn |0 (DE-588)120340534 |0 (DE-627)080614140 |0 (DE-576)29216761X |4 aut | |
| 700 | 1 | |a Storch-Hagenlocher, Brigitte |e VerfasserIn |0 (DE-588)107437892X |0 (DE-627)832083208 |0 (DE-576)442632061 |4 aut | |
| 700 | 1 | |a Sertel, Serkan |d 1974- |e VerfasserIn |0 (DE-588)173510221 |0 (DE-627)698422635 |0 (DE-576)134355059 |4 aut | |
| 700 | 1 | |a Elsässer, Michael |e VerfasserIn |0 (DE-588)1051654092 |0 (DE-627)786526408 |0 (DE-576)406993815 |4 aut | |
| 700 | 1 | |a Remppis, Bjoern-Andrew |d 1961- |e VerfasserIn |0 (DE-588)112494986 |0 (DE-627)509446701 |0 (DE-576)289733294 |4 aut | |
| 700 | 1 | |a Munzinger, Judith |e VerfasserIn |0 (DE-588)1074761731 |0 (DE-627)832534552 |0 (DE-576)442942818 |4 aut | |
| 700 | 1 | |a Edler, Lutz |d 1945- |e VerfasserIn |0 (DE-588)143483293 |0 (DE-627)646571796 |0 (DE-576)167028103 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Strowitzki, Thomas |d 1959- |e VerfasserIn |0 (DE-588)118055917 |0 (DE-627)079216099 |0 (DE-576)17102141X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Phytomedicine |d München [u.a.] : Elsevier, 1994 |g 54(2019), Seite 140-148 |h Online-Ressource |w (DE-627)325793352 |w (DE-600)2040195-4 |w (DE-576)116691972 |x 1618-095X |7 nnas |a Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2) |
| 773 | 1 | 8 | |g volume:54 |g year:2019 |g pages:140-148 |g extent:9 |a Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2) |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phymed.2018.09.178 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190403 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 118055917 |a Strowitzki, Thomas |m 118055917:Strowitzki, Thomas |d 910000 |d 910400 |e 910000PS118055917 |e 910400PS118055917 |k 0/910000/ |k 1/910000/910400/ |p 12 |y j | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 11 | ||
| 998 | |g 143483293 |a Edler, Lutz |m 143483293:Edler, Lutz |d 50000 |e 50000PE143483293 |k 0/50000/ |p 9 | ||
| 998 | |g 1074761731 |a Munzinger, Judith |m 1074761731:Munzinger, Judith |d 910000 |d 999701 |e 910000PM1074761731 |e 999701PM1074761731 |k 0/910000/ |k 1/910000/999701/ |p 8 | ||
| 998 | |g 112494986 |a Remppis, Bjoern-Andrew |m 112494986:Remppis, Bjoern-Andrew |d 910000 |d 910100 |e 910000PR112494986 |e 910100PR112494986 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1051654092 |a Elsässer, Michael |m 1051654092:Elsässer, Michael |d 910000 |d 910400 |e 910000PE1051654092 |e 910400PE1051654092 |k 0/910000/ |k 1/910000/910400/ |p 6 | ||
| 998 | |g 173510221 |a Sertel, Serkan |m 173510221:Sertel, Serkan |d 910000 |d 911000 |e 910000PS173510221 |e 911000PS173510221 |k 0/910000/ |k 1/910000/911000/ |p 5 | ||
| 998 | |g 107437892X |a Storch-Hagenlocher, Brigitte |m 107437892X:Storch-Hagenlocher, Brigitte |d 910000 |d 911100 |e 910000PS107437892X |e 911100PS107437892X |k 0/910000/ |k 1/910000/911100/ |p 4 | ||
| 998 | |g 120340534 |a Goeckenjan, Maren |m 120340534:Goeckenjan, Maren |d 50000 |e 50000PG120340534 |k 0/50000/ |p 3 | ||
| 998 | |g 1065347987 |a Walter-Sack, Ingeborg |m 1065347987:Walter-Sack, Ingeborg |d 910000 |d 910100 |e 910000PW1065347987 |e 910100PW1065347987 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1069452521 |a Hagens, Cornelia von |m 1069452521:Hagens, Cornelia von |d 910000 |d 910400 |e 910000PH1069452521 |e 910400PH1069452521 |k 0/910000/ |k 1/910000/910400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1662773706 |e 3417898730 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)","title":"Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)"}],"person":[{"role":"aut","given":"Cornelia von","family":"Hagens","display":"Hagens, Cornelia von"},{"family":"Walter-Sack","role":"aut","given":"Ingeborg","display":"Walter-Sack, Ingeborg"},{"family":"Goeckenjan","role":"aut","given":"Maren","display":"Goeckenjan, Maren"},{"family":"Storch-Hagenlocher","role":"aut","given":"Brigitte","display":"Storch-Hagenlocher, Brigitte"},{"display":"Sertel, Serkan","given":"Serkan","role":"aut","family":"Sertel"},{"given":"Michael","role":"aut","family":"Elsässer","display":"Elsässer, Michael"},{"display":"Remppis, Bjoern-Andrew","given":"Bjoern-Andrew","role":"aut","family":"Remppis"},{"given":"Judith","role":"aut","family":"Munzinger","display":"Munzinger, Judith"},{"display":"Edler, Lutz","role":"aut","given":"Lutz","family":"Edler"},{"display":"Schneeweiss, Andreas","role":"aut","given":"Andreas","family":"Schneeweiss"},{"role":"aut","given":"Thomas","family":"Strowitzki","display":"Strowitzki, Thomas"}],"recId":"1662773706","name":{"displayForm":["Cornelia von Hagens, Ingeborg Walter-Sack, Maren Goeckenjan, Brigitte Storch-Hagenlocher, Serkan Sertel, Michael Elsässer, Bjoern A. Remppis, Judith Munzinger, Lutz Edler, Thomas Efferth, Andreas Schneeweiss, Thomas Strowitzki"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"id":{"doi":["10.1016/j.phymed.2018.09.178"],"eki":["1662773706"]},"note":["Gesehen am 03.04.2019"],"relHost":[{"note":["Fortsetzung der Druckausgabe","Gesehen am 13.06.2023"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"pubHistory":["1.1994/95 -"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Phytomedicine","subtitle":"international journal of phytotherapy and phytopharmacology","title_sort":"Phytomedicine"}],"recId":"325793352","disp":"Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)Phytomedicine","origin":[{"dateIssuedDisp":"1994-","publisher":"Elsevier ; Urban & Fischer","dateIssuedKey":"1994","publisherPlace":"München [u.a.] ; Jena"}],"id":{"eki":["325793352"],"issn":["1618-095X"],"zdb":["2040195-4"]},"part":{"year":"2019","extent":"9","text":"54(2019), Seite 140-148","pages":"140-148","volume":"54"}}]} | ||
| SRT | |a HAGENSCORNLONGTERMAD2019 | ||